Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms
- 14 July 2009
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (28) , 11697-11702
Abstract
A variety of mechanisms maintain the integrity of the genome in the face of cell stress. Cancer cell response to chemotherapeutic and radiation-induced DNA damage is mediated by multiple defense mechanisms including polo-like kinase 1 (Plk-1), protein kinase B (Akt-1), and/or p53 pathways leading to either apoptosis or cell cycle arrest. Subsequently, a subpopulation of arrested viable cancer cells may remain and recur despite aggressive and repetitive therapy. Here, we show that modulation (activation of Akt-1 and Plk-1 and repression of p53) of these pathways simultaneously results in paradoxical enhancement of the effectiveness of cytotoxic chemotherapy. We demonstrate that a small molecule inhibitor, LB-1.2, of protein phosphatase 2A (PP2A) activates Plk-1 and Akt-1 and decreases p53 abundance in tumor cells. Combined with temozolomide (TMZ; a DNA-methylating chemotherapeutic drug), LB-1.2 causes complete regression of glioblastoma multiforme (GBM) xenografts without recurrence in 50% of animals (up to 28 weeks) and complete inhibition of growth of neuroblastoma (NB) xenografts. Treatment with either drug alone results in only short-term inhibition/regression with all xenografts resuming rapid growth. Combined with another widely used anticancer drug, Doxorubicin (DOX, a DNA intercalating agent), LB-1.2 also causes marked GBM xenograft regression, whereas DOX alone only slows growth. Inhibition of PP2A by LB-1.2 blocks cell-cycle arrest and increases progression of cell cycle in the presence of TMZ or DOX. Pharmacologic inhibition of PP2A may be a general method for enhancing the effectiveness of cancer treatments that damage DNA or disrupt components of cell replication.Keywords
This publication has 28 references indexed in Scilit:
- Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaJournal of Clinical Oncology, 2009
- Targeting Polo-Like Kinase: Learning Too Little Too Late?Journal of Clinical Oncology, 2008
- The genetics of the p53 pathway, apoptosis and cancer therapyNature Reviews Drug Discovery, 2008
- Recent advances in p53 research: an interdisciplinary perspectiveCancer Gene Therapy, 2008
- Drug discovery approaches targeting the PI3K/Akt pathway in cancerOncogene, 2008
- Tankyrase 1 and Tankyrase 2 Are Essential but Redundant for Mouse Embryonic DevelopmentPLOS ONE, 2008
- Living on a break: cellular senescence as a DNA-damage responseNature Reviews Cancer, 2008
- Phosphorylation of MDMX Mediated by Akt Leads to Stabilization and Induces 14-3-3 BindingJournal of Biological Chemistry, 2008
- Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpointOncogene, 2008
- TCTP protects from apoptotic cell death by antagonizing bax functionCell Death & Differentiation, 2008